The significant stock price increase of 150% is directly attributed to the positive clinical trial results of INT230-6, which is a key product for Intensity Therapeutics. The data presented at a major symposium suggests potential efficacy and safety, which are critical factors for investors in the biotech sector. The news is highly relevant and important to the company's valuation, and the confidence in this analysis is high due to the clear cause-and-effect relationship between the trial results and the stock price movement.